Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 14, 2015; 21(14): 4284-4292
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4284
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4284
Figure 1 Flow diagram.
HBV: Hepatitis B virus; allo-HSCT: Allogeneic hematopoietic stem cell transplantation; HBcAb: Hepatitis B core antibody; HBsAg: Hepatitis B surface antigen.
Figure 2 Cumulative survival rates in the non-hepatitis B virus infection group, HBsAg-positive group and HBsAg-negative/HBcAb positive group after allogeneic hematopoietic stem cell transplantation.
HBcAb: Hepatitis B core antibody; HBsAg: Hepatitis B surface antigen.
- Citation: Liao YP, Jiang JL, Zou WY, Xu DR, Li J. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. World J Gastroenterol 2015; 21(14): 4284-4292
- URL: https://www.wjgnet.com/1007-9327/full/v21/i14/4284.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i14.4284